List of Excipients in API lazertinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing lazertinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | CELLULOSE, MICROCRYSTALLINE | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | CROSCARMELLOSE SODIUM | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | FERRIC OXIDE RED | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | FERROSOFERRIC OXIDE | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | GLYCERYL MONOCAPRYLOCAPRATE | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | MAGNESIUM STEARATE | 2029-08-19 |
| Janssen Biotech Inc | LAZCLUZE | lazertinib | 57894-240 | MANNITOL | 2029-08-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for lazertinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
lazertinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
lazertinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
lazertinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
lazertinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONOCAPRYLOCAPRATE
lazertinib drug variants containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
lazertinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
lazertinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
lazertinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
lazertinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
lazertinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
lazertinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
lazertinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | lazertinib | 57894-240 |
| >Company | >Ingredient | >NDC |
lazertinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch